Helius Medical Technologies Inc (NASDAQ:HSDT) shares are rising Monday after the company announced a positive outcome from the Portable Neuromodulation Stimulator (PoNS) Stroke Registrational Program.
What Happened: Micro-cap Helius Medical said key primary outcomes indicate its double-blind randomized clinical trial of active PoNS therapy met its primary endpoint, demonstrating statistically significant improvements in gait and/or balance deficit due to stroke. The company noted the study showed good tolerability and minimal adverse event incidents.
